$54.33
7.44% today
Nasdaq, Feb 28, 04:49 pm CET
ISIN
US69366J2006
Symbol
PTCT
Sector
Industry

PTC Therapeutics, Inc. Stock price

$50.57
+4.50 9.77% 1M
+15.25 43.18% 6M
+5.43 12.03% YTD
+22.26 78.63% 1Y
+15.45 43.99% 3Y
-2.97 5.55% 5Y
-20.76 29.10% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.39 0.77%
ISIN
US69366J2006
Symbol
PTCT
Sector
Industry

Key metrics

Market capitalization $3.90b
Enterprise Value $3.29b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.65
P/S ratio (TTM) P/S ratio 4.33
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 12.84%
Revenue (TTM) Revenue $900.66m
EBIT (operating result TTM) EBIT $-127.76m
Free Cash Flow (TTM) Free Cash Flow $-186.27m
Cash position $1.01b
EPS (TTM) EPS $-5.94
P/E forward negative
P/S forward 4.89
EV/Sales forward 4.13
Short interest 7.46%
Show more

Is PTC Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

PTC Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a PTC Therapeutics, Inc. forecast:

9x Buy
60%
3x Hold
20%
3x Sell
20%

Analyst Opinions

15 Analysts have issued a PTC Therapeutics, Inc. forecast:

Buy
60%
Hold
20%
Sell
20%

Financial data from PTC Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
901 901
13% 13%
100%
- Direct Costs 205 205
10% 10%
23%
696 696
22% 22%
77%
- Selling and Administrative Expenses 143 143
2% 2%
16%
- Research and Development Expense 531 531
28% 28%
59%
22 22
107% 107%
2%
- Depreciation and Amortization 150 150
26% 26%
17%
EBIT (Operating Income) EBIT -128 -128
75% 75%
-14%
Net Profit -453 -453
29% 29%
-50%

In millions USD.

Don't miss a Thing! We will send you all news about PTC Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

PTC Therapeutics, Inc. Stock News

Neutral
Seeking Alpha
about 14 hours ago
PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Ellen Cavaleri - Head of IR Matthew Klein - CEO Eric Pauwels - Chief Business Officer Pierre Gravier - CFO Conference Call Participants Kristen Kluska - Cantor Fitzgerald Eric Joseph - JPMorgan Kelly Shi - Jefferies Tiago Fauth - Wells Fargo Eli Merle - UBS Gena Wang - Barcla...
Neutral
PRNewsWire
about 19 hours ago
– Full year 2024 revenue of $807 million, exceeding guidance – – All 2024 clinical and regulatory milestones were achieved on schedule, including four NDA submissions, all of which were accepted for filing – – License and collaboration agreement with Novartis for PTC518 Huntington's disease program closed in January 2025 – – Cash of over $2.0 billion as of January 2025 – WARREN, N.J. , Feb. 27,...
Neutral
PRNewsWire
8 days ago
WARREN, N.J. , Feb. 20, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will participate in fireside chats at the following investor conferences: TD Cowen 45th Annual Health Care 2025 Conference   Tuesday, March 4 at 11:10 a.m.
More PTC Therapeutics, Inc. News

Company Profile

PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically-differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.

Head office United States
CEO Matthew Klein
Employees 995
Founded 1998
Website www.ptcbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today